Interaction between IgA and gut microbiota and its role in controlling metabolic syndrome.
Jielong GuoXue HanWeidong HuangYilin YouJi-Cheng ZhanPublished in: Obesity reviews : an official journal of the International Association for the Study of Obesity (2020)
Immunoglobulin A (IgA) is the most abundant immunoglobulin isotype secreted into the mucosal tissues, mainly intestinal mucus. Humans can produce several grams of IgA every day, accounting for three quarters of the body's total immunoglobulin content. IgA, together with mucus and antimicrobial peptides, forms the first line of defence for intestinal epithelial cells, protecting them from a significant number of intestinal antigens. IgA also plays a principal role in controlling the gut microbiota (GM), and disruption in IgA can result in dysbiosis, such as the enrichment of Proteobacteria, which are generally bound by IgA. Proteobacteria overexpansion is also usually seen in obesity and colitis. Consistent with this, IgA dysfunction frequently results in metabolic syndrome (MetS), including conditions such as obesity, adiposity, insulin resistance, and inflammation. In contrast, enhanced IgA function can improve, and even prevent, MetS. Interactions among IgA, GM, and metabolism provide a promising avenue to combat MetS.
Keyphrases
- metabolic syndrome
- insulin resistance
- type diabetes
- contrast enhanced
- magnetic resonance imaging
- adipose tissue
- uric acid
- high fat diet induced
- skeletal muscle
- gene expression
- weight gain
- physical activity
- dendritic cells
- polycystic ovary syndrome
- cardiovascular risk factors
- ulcerative colitis
- diffusion weighted imaging